A New Weight-Loss Drug Just Outperformed Popular GLP-1s—What It Means for the Future of Health
Retatrutide’s Clinical Breakthrough: Why Eli Lilly’s Experimental Drug Could Reshape the Weight-Loss Market For the past two years, the GLP-1 receptor agonist category—dominated by Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly’s Mounjaro—has been the undisputed heavyweight champion of metabolic health interventions. Sales numbers alone tell the story: combined global revenue for these therapies exceeded…